EuroPD 2009 - PD For Alleuropd2017.crushdigital.co.uk/wp-content/uploads/... · Overview of the anatomy of the peritoneal membrane, basic understanding of small solute transport and

The 9th European Peritoneal Dialysis Meeting. 9th - 12th October 2009. Palais des Congrés, Strasbourg.

Final Programme

www.europd.com

EuroPD 2009 - PD For All

EPD Final Prog A5.indd 1 29/9/09 11:36:50

2 3

Peritoneal Dialysis

Protect Preserve ProlongUpgrade to Comprehensive PD

Anz_P3_EuroPD-Prog_09.09_GB.indd 1 21.09.09 10:18EPD Final Prog A5.indd 2 29/9/09 11:36:56

2 3 www.europd.com

Palais des Congrés, Strasbourg

Contents Page

Organising Committees 4

Welcome 5

Scientific Programme 7

Additional Information 25

Exhibitors and Sponsors 27

Congress Centre Plans 30

Platinum Sponsors The organisers greatly appreciate the support of the following companies

Conference Organisers In Conference Ltd 4-6 Oak Lane Edinburgh, EH12 6XH Scotland, UK

Tel: +44 (0)131 339 9235 Fax: +44 (0)131 339 9798

Email: [email protected] Web: www.europd.com

EuroPD 2009 | 9th European Peritoneal Dialysis Meeting

Peritoneal Dialysis

Protect Preserve ProlongUpgrade to Comprehensive PD

Anz_P3_EuroPD-Prog_09.09_GB.indd 1 21.09.09 10:18EPD Final Prog A5.indd 3 29/9/09 11:37:01

4

EuroPD 2009 | Final Programme

EuroPD 2009 | 9th European Peritoneal Dialysis Meeting 4 5www.europd.com

Organising CommitteesScientific Programme Committee John Williams, (Chair) Cardiff, UK Simon Davies, (Chair, Programme Committee), Stoke on Trent, UK Michel Fischbach, Strasbourg, France Achim Jörres, Berlin, Germany Nick Topley, Cardiff, UK Wim Van Biesen, (Co-Chair, Programme Committee), Gent, Belgium Christian Verger, Pontoise, France

Local Organising Committee Michel Fischbach, Strasbourg (President) Christian Verger, Pontoise (Vice-President) Belkacem Issad, Paris Eric Boulanger, Lille Pierre Yves Durand, Quimper Bernadette Faller, Colmar Joelle Terzic, Strasbourg Thierry Hannedouche, Strasbourg Jean-Philippe Ryckelynck, Caen Franz Schaefer, Heidelberg Michel Tsimaratos, Marseille

Representing: Société de Néphrologie Société Francophone de Dialyse Société de Néphrologie Pédiatrique Registre de Dialyse Péritonéale de Langue Française


44 5 www.europd.com


Welcome On behalf of the Local and Scientific Committees, it is my pleasure to welcome you to the 9th European Peritoneal Dialysis meeting here in Palais des Congrés, Strasbourg.

Following on from the previous meetings in Helsinki, Prague, Berlin, Gent, Edinburgh, Madrid, Brussels and Amsterdam the 9th EuroPD meeting will once again bring together scientists and clinicians interested in advancement of this mode of therapy in order to share knowledge and debate new developments.

The main theme of the conference is ‘PD for All’. It will seek to explore and offer guidance on how peritoneal dialysis can be optimised to give patients from different demographics and with varying comorbid diseases the opportunity to use PD and to get the best clinical outcomes.

Scientific Symposia will be linked to Clinical Practice Sessions in topic areas such as PD in the elderly, children, diabetics, heart failure and infection. The symposia will combine the expert views of generalists and PD specialists.

Promoting delegate involvement will also be a major goal of the integrated programme. There will be several sessions devoted to debating some of the most controversial issues in PD today. It is our great pleasure to welcome you to EuroPD in Strasbourg.

Professor Simon Davies (Chair, Scientific Programme Committee) Professor Wim Van Biesen (Co-Chair, Scientific Programme Committee) Professor Michel Fischbach (President, Local Organising Committee)


6 7

S p é c i a l i s t e d e l a v i eE x p e r t o f l i f e

Néphrologie (Hyperphosphorémie du dialysé)

TDAH (Troubles déficits de l’attention / hyperactivité)

Gastroentérologie (Colite ulcérative)

Maladies génétiques rares(Maladie de Fabry, syndrome de Hunter)

Notre priorité : la Recherche et le Développementde nouvelles molécules dans 4 domaines majeurs

Pour en savoir plus, visitez notre site internet : www.shire.comSHIRE France S.A. - 88 rue du Dôme - 92514 Boulogne-Billancourt Cedex

COPP

ELIA

Créd

itph

oto

:©D

igita

lVis

ion

Juin

2009

Our priority: The Research and Developmentof new molecules in 4 major areas:

Nephrology

ADHD

Gastroenterology

Rare genetic diseases

For more information, visit our website: www.shire.comShire Plc, Hampshire International Business Park, Chineham, Basingstoke, RG24 8EPCO

PPEL

IAPh

oto

cred

it:©

Dig

italV

isio

nJu

ne20

09


6 7 www.europd.com

Palais des Congrés, StrasbourgS p é c i a l i s t e d e l a v i e

E x p e r t o f l i f e

Néphrologie (Hyperphosphorémie du dialysé)

TDAH (Troubles déficits de l’attention / hyperactivité)

Gastroentérologie (Colite ulcérative)

Maladies génétiques rares(Maladie de Fabry, syndrome de Hunter)

Notre priorité : la Recherche et le Développementde nouvelles molécules dans 4 domaines majeurs

Pour en savoir plus, visitez notre site internet : www.shire.comSHIRE France S.A. - 88 rue du Dôme - 92514 Boulogne-Billancourt Cedex

COPP

ELIA

Créd

itph

oto

:©D

igita

lVis

ion

Juin

2009

Our priority: The Research and Developmentof new molecules in 4 major areas:

Nephrology

ADHD

Gastroenterology

Rare genetic diseases

For more information, visit our website: www.shire.comShire Plc, Hampshire International Business Park, Chineham, Basingstoke, RG24 8EPCO

PPEL

IAPh

oto

cred

it:©

Dig

italV

isio

nJu

ne20

09

Scientific Programme Friday 9th October 2009 – MAIN CONFERENCE10.00–18.00 Registration Open Entrance Erasme

10.00–18.00 Speaker Presentation Check-In Salon President

Friday 9th October 2009 - Pre Conference Educational Course I13.00–16.00 Pre-Conference Educational

Paediatric CourseCost: €50 - (Places must be pre-booked)

Chairs: F Schaefer, Heidelberg, Germany; B Warady, Kansas City, USA

13.00–13.30 PD Prescription: Fill Volume, Dwell Time M Fischbach, Strasbourg, FranceHow to prescribe a fill volume from babies to adolescents; which impact on tolerance and dialysis efficacy; the importance of the dwell time on ultrafiltration and purification

13.30–14.00 PD Prescription: The PDFs ChoiceC Schmitt, Heidelberg, GermanyFrom composition to biocompatibility of the peritoneal dialysis fluids. Discuss the clinical place for the new PDFs

14.00–14.30 Assessment of the Peritoneal Membrane: Is the PET Enough? B Warady, Kansas City, USAHow to test peritoneal membrane permeability; when and how to prescribe a PET; impact on prescription and outcome (hyperpermeability, hypopermeability: risks)

14.30–15.00 Tea/Coffee

15.00–15.30 Peritonitis: How to Manage it? F Schaefer, Heidelberg, GermanyHow to define a peritonitis; what to do in terms of first choice for antibiotic treatment; how to prescribe peritoneal dialysis over a peritonitis episode, how to prevent

15.30–16.00 The Peritoneal Catheter J Terzic, and F Becmeur, Strasbourg, FranceThe catheter choice, the catheter placement, the catheter follow up, from babies to adolescents, a need for adequate management.

Kleber


8


EuroPD 2009 | 9th European Peritoneal Dialysis Meeting 8 9

Friday 9th October 2009 - Pre Conference Educational Course II13.00–16.00 Pre-Conference Educational Course II

Cost: €50 - (Places must be pre-booked)Chairs: W Van Biesen, Gent, Belgium; B Faller, Colmar, France

13.00–13.20 Peritoneal Physiology and AnatomyS Fan, London, UKOverview of the anatomy of the peritoneal membrane, basic understanding of small solute transport and sodium sieving, 3 pore theory

13.20–13.40 Peritoneal Cell Populations and their Relevance to Clinical PDG Roberts, Cardiff, UKOverview of the resident cell populations in the peritoneal cavity and the peritoneal membrane, and how their function changes with PD duration and during infection.

13.40–14.00 Treatment Strategies for PD Related PeritonitisR Krediet, Amsterdam, The NetherlandsRisk factors for peritonitis, the prevention of peritonitis, the need for epidemiologic studies, key issues when developing an empirical antibiotic therapy strategy.

14.00–14.20 Volume Management in PDS Davies, Stoke on Trent, UKVolume status in PD, importance of residual renal function, evaluation methods of volume status, how to achieve euvolemia.

14.20–14.50 Tea/Coffee

14.50–15.10 Optimal Clearance in PDW Van Biesen, Gent, BelgiumImportance of small solute clearance, improving small solute clearance, avoiding high volume regimens, dwell time, dwell volumes, breakpoint analysis.

15.10–15.30 Enlarging the PD PopulationJ D Williams, Cardiff, UKStrategies to enhance the numbers of incident patients starting on PD and strategies to improve technique success

15.30–15.50 Opportunities and Pitfalls of Assisted CareC Verger, Pontoise, FranceDifferent strategies to implement assisted care and different levels of assisted care

15.50-16.00 Discussion

Schuman


88 9 www.europd.com


Friday 9th October 2009 – MAIN CONFERENCE10.00-18.00 Registration Open

Speaker Presentation Check-InEntrance Erasme Salon President

16.30-18.00 Welcome & Opening PlenaryChairs: J D Williams, Cardiff, UK; M Fischbach, Strasbourg, France

16.30-16.40 Welcome

16.40–17.10 Cultural Event: - Ecole de Musique de Schiltigheim (Claude Siegwald) - Harpist School (Marie Madelaine Sigward)- Les Petits Chanteurs de Strasbourg (Philippe Utard)

17.10–18.00 The Evolving Landscape of European Renal Replacement Therapies: What We Can Learn From the ANZDATA D Johnson, Brisbane, Australia

Erasme Hall

18.00-19.30 Industry Symposium I

Hyperphosphatemia; Early Management and Treatment Considerations to Improve Patient OutcomesChair: Prof. J Bommer, Medical Clinic, University of Heidelberg, Germany Calcium MythsDr. C. Ferro, Queen Elizabeth Hospital, Birmingham, UK Early Management of Hyperphosphatemia and its Treatment With a Novel TherapyProf. J Bommer, Medical Clinic, University of Heidelberg, Germany

Q&A Session

Erasme Hall

19.30–21.00 Opening of the Exhibition and 9th EuroPD Welcome Reception Supported by

Exhibition Foyer


10



Saturday 10th October 200907.00–18.45 07.00–18.45

10.00–17.30

Registration and Posters OpenSpeaker Presentation Check-In

Exhibition & Internet Cafe Open

Entrance Erasme Salon President

Exhibition Foyer

Masterclasses: Session I(by invitation only)

07.45–08.30 Theme A1: Peritoneal Dialysis AdequacyO Heimburger, Stockholm, Sweden

07.45–08.30 Theme B1: Peritoneal Dialysis and Access A Slingeneyer, Montpellier, France

07.45–08.30 Theme C1: Assessment of Peritoneal Transport Characteristics S Davies, Stoke on Trent, UK; B Rippe, Lund, Sweden

Kleber

Rohan

Gutenberg

08.30–10.00 Symposium I

PD in the Diabetic PatientChairs: W Van Biesen, Gent, Belgium; B Issad, Paris, France

08.30-08.50 Adipocyte Metabolism in Chronic Renal Failure and Dialysis L Ranganath, Liverpool, UK

08.50-09.10 Recent Advances in the Relationship Between Inflammation, Obesity and Insulin ResistanceJP Bastard, Paris, FranceType 2 diabetes is linked to obesity and insulin resistance. PD can also be linked to obesity and insulin resistance, due to the enhanced glucose uptake. How can our current understanding of the pathophysiology of type 2 diabetes help us to understand the eventual link between PD and diabetes? What is the role of the adipocyte in the chronic inflammation observed in PD patients? And what is the link between inflammation and insulin resistance? Can this be the explanation for the observed higher mortality in older female diabetic PD vs HD patients?

09.10-09.35 Treatment Regimens for Diabetes In 2009M Giri, Ghent, BelgiumOptimal control of glucose is key to improve survival in diabetic patients. What are the current treatment strategies for diabetic patients (especially type 2) with chronic renal failure: new insulins, new oral drugs, the place of methformin, thiazolidines or glipinide, physical exercise, diet.

09.35-10.00 Metabolic and Symptom Control in Diabetic Patients on PDO Heimburger, Stockholm, SwedenWhat is the impact of PD on diabetes? How many PD patients develop diabetes? Evolution of glycemic control? PD practice and its impact on diabetes, e.g. use of hypertonic exchanges. Treatment of polyneuropathy? Impact of glucose on haemodynamic parameters? The diabetic foot in PD patients? Lipid profiles and treatment?

Erasme Hall


1010 11 www.europd.com


10.00-10.30 Tea/Coffee Exhibition Foyer

10.30-12.00 Symposium IIa

Paediatric Experiences of Interest for Adult CareChairs: J Vandewalle, Gent, Belgium ; B Warady, Kansas City, USA

10.30-11.00 Improving PD for Children Worldwide. The Impact of the International Paediatric Peritoneal Dialysis Network B Warady, Kansas City, USA

11.00-11.20 Gastrostomy in PD Patients: Risky?A Edefonti, Milan, Italy

11.20-11.40 Dialysis for Acute Metabolic Diseases: Is there a Place for PD? C Stefanidis, Athens, Greece

11.40-12.00 Impact of the PDFs on the Membrane Permeability C Schmitt, Heidelberg, Germany

Salle Schuman

10.30-12.00 Symposium IIb

PD in the Elderly Patient: Chairs: C Verger, Pontoise, France; E Brown, London, UK

10.30-10.55 Evaluation of Cognitive and Physical Function in the Elderly N Van De Noorgate, Gent, BelgiumA correct estimation of the mental and cognitive function of elderly patients is crucial in the decision making process regarding dialysis: yes or no RRT, type of RRT, can the patient remain at home, or should he/she be transferred to a nursing home? How can we correctly evaluate the physical and mental function of our patients to support these decisions. What is their predictive/diagnostic value; Are there “objective” investigations (Scans, PET, MR,?) that can be of help.

10.55-11.15 Cognitive and Physical Function in the Elderly Dialysis Patient: Strategies for Improvement? V Jassal, Toronto, CanadaHow can we stimulate our patients to improve their cognitive skills and their physical powers? Physiotherapy? Electrostimulation? Dietary measures?

11.15-11.40 What are the Barriers to PD in the Elderly: Outcomes of the BOLDE Study E Brown, London, UKMany consider older age and lower physical and mental condition a contra-indication for PD. Is this really the case, or can solutions be found to make PD a good and valuable alternative to HD?

11.40-12.00 Associations Between Comorbidities, Treatment Choice and Outcome in The Elderly with End-Stage Renal DiseaseT Lobbedez, Caen, FranceDescription of the results obtained in France.

Erasme Hall

12.00–14.00 Lunch/Posters/Exhibition (Lunch can be taken into the auditorium for the Fresenius symposium)

Exhibition Foyer

Saturday 10th October continued


12



12.15–13.45 Industry Symposium II

Improving Outcomes with Modern Therapy Concepts

Chairs: Achim Jörres, Berlin, Germany; John D Williams, Cardiff, Wales Biocompatible Low GDP - PD Solutions - A Treatment For All Patients?M Feriani, Mestre, Italy Peritoneal Dialysis In Children: How Adapted Fill Volume and Dwell Time Improve PD EfficiencyM Fischbach, Strasbourg, France Volume Status In PD Patients: Facts And Fiction W Van Biesen, Gent, Belgium

Erasme Hall

13.45-15.00 Poster Session I

ANIMOD - Posters: P1 – P5P Ter Wee, The Netherlands; J Witowski, Poland; R Selgas, Spain Cardiovascular - Posters : P6 – P15J Heaf, Denmark; PY Durand, France,

Clinical PD - Posters: P16-P37O Heimburger, Sweden; B Faller, France; J Chanliau, France; B Bammens, Belgium

Paediatrics - Posters: P109, P143 - P145A Edefonti, Italy; D Stefanidis, Greece Other - Posters: P-124-P142E Brown, UK; E Goffin, Belgium

Ground Floor

14.00-15.00 Mini Symposium I

The Place of PD in the Intensive Care UnitChairs: A Jorres, Berlin, Germany; M Tsimaratos, Marseille, France

PD is often not considered as a good alternative for other extracorporeal techniques in ICU patients with ARF.

14.00-14.30 PD for Paediatric Patients at ICU: Tips and Tricks J Vandewalle, Gent, BelgiumIn small children, PD is often used as an alternative for extracorporeal treatment. What are the key points to make it a successful treatment: access, solutions, ultrafiltration, clearance; tolerance (IPP), exchange permeability, its place in cases of HUS or post cardiac surgery will be discussed.

14.30-15.00 Is There still a Place for PD in Adults at ICU? A Jorres, Berlin, GermanyMany consider PD as inadequate in the catabolic patients with ARF at ICU. In contrast, PD has some advantages: haemodynamic stability, no requirement for anticoagulation, no changes in intracerebral pressure or perfusion. What can be ideal indications for PD at ICU? What should be yhe key points to make it a good and successful treatment? Access? Clearance? Ultrafiltration? Solutions?

Erasme Hall





14.00-15.00 Free Communications I

Clinical Session Chair: Wim Van Biesen, Gent, Belgium

14.00-14.12 - O-1 Quality of Life in Older Peritoneal and Haemodialysis Patients: Results from the BOLDE Study Lina Johansson, Nigel Beckett, Maria Da Silva-Gane, Ken Farrington, Hugh Gallagher, Mary Hickson, Tom Sensky, Edwina Brown

14.12-14.24 - O-2 Engendering Hope in Patients Receiving Dialysis Treatment. Dialysis Patient’s Illustration of Hope, the Related Factors and Helping Methods Sinikka Kuohula

14.24-14.36 - O-3 The Apd Treatment with a Cycler Personalised Breakpoint improves Peritoneal Dialytic Kt/V: A Pilot Study Roberto Dell’Aquila, Ivo Baragetti, Marco Pozzi, G. Berlingò, Elena Alberghini, Lucia Pisano, Andrea Galassi, Claudio Pozzi, Renzo Scanziani

15.36-15.48 - O-4 The Patient Pathway - Improving the Patient’s Transition from CKD to Peritoneal Dialysis Lesley Lappin, David Lewis, Annette Knaggs, Sarah Bridgford

15.48-15.00 - O-5 Are Survival Curves in Peritoneal Dialysis False? The Importance of Competing Risks in Survival Analysis Jean Baptiste Beuscart, Dominique Pagniez, Eric Boulanger, Celia Lessore De Sainte Foy, Julia Salleron, Luc Frimat, Alain Duhamel

Schuman Room



14



15.00–17.00 Clinical Practice Session I

PD in the Frail PatientChairs: M Dratwa, Brussels, Belgium; J Chanliau, Nancy, France

15.00-15.40 Mini-Debate: Offering Assisted PD to the Elderly is Mandatory to Expand Patient Numbers

CON: P Ter Wee, Amsterdam, The NetherlandsPRO: J Heaf, Herlev, Denmark

Can the development and support of assisted PD result in an increase in prevalence of PD?

15.40-16.05 Starting Patients Who are Referred Late on PDT Lobbedez, Caen, FranceThe majority of patients referred late still end up on HD, and do not transfer back to PD. There are however some clear advantages to PD even in late referrals: no need for indwelling catheters, slow and gentle treatment preserving residual renal function and avoiding disequilibrium. Starting PD in late referrals requires some specific logistical approaches: access, starting regimens, education. Several reports are now available of successful programs with late referred patients on PD.

16.05-16.30 Treating PD Patients with Congestive Heart failureA Vychytil, Wien, AustriaThe prevalence of congestive heart failure is increasing rapidly, paradoxically because of the better care for cardiovascular care for patients. Most of these patients have also renal failure, and there is a constant search for equilibrium between good cardiac and renal function. Can PD be a solution for these patients? Which modalities/ regimens should be preferred? Pathophysiology: is it only fluid removal, or is there more going on?

16.30-17.00 Advance Care Planning and End of Life Care in ESRDJ Chambers, Bristol, UKThere is an increasing interest in “non dialysis” in frail patients, but in those who do not want to refrain completely, or for control of uremic symptoms, PD can be a suitable “palliative” RRT modality, where the “care” is the first issue of concern. Alternatively, in patients on long term RRT, there can come a moment when poor QoL becomes an issue. What should be done in these circumstances? Strategies of advanced care planning, therapy restrictions, caring not curing protocols.

Erasme Hall





17.15-18.45 Industry Symposium III

More choices for AllChairman: M Fischbach, Strasbourg, France

Co-chairman: C Verger, Pontoise, France

Starting Dialysis for All- Challenges of Unplanned Start, Consequences, Possible Approaches Including the Unplanned Start ProgrammeIngrid Keur - The Netherlands

PD Prescribing for All- Practical case based, key aspects of PD prescribing (UF, Small solute, role of CAPD/APD)Max Dratwa - Belgium

Benefits of Biocompatible Solutions for All - Results of “late breaking” Study of Biocompatible Fluids From KoreaDae Suk Han - Korea

Choice of Home Dialysis for All- Home vs. Centre Choice, Integration of Modalities for Improved OutcomesRichard Fluck - United Kingdom

Erasme Hall



16



Sunday 11th October 200907.30-18.1507.30-18.15

10.30-17.30


Exhibition Open


Ground Floor & Exhibition Foyer

Masterclasses A2/B2/C2

07.45-08.30 Theme A2: Volume Management on Peritoneal Dialysis J Heaf, Herlev, Denmark

07.45-08.30 Theme B2: PD in Specific Patient GroupsE Goffin, Brussels, Belgium

07.45-08.30 Theme C2: Growth Factors and Cytokines Relevant to PD E Boulanger, Lille, France

Gutenberg

Kleber

Rohan

08.30-10.30 Symposium III

Infection and Peritoneal DialysisChairs: J D Williams, Cardiff, UK; B Faller, Colmar, France

08.30-08.55 The Risk of Infection and its Complication are Worse in HD Than in PDE Goffin, Brussels, BelgiumFor most nephrologists, infection is “the” problem in PD. However, when looking to the alternative modality, HD, it is clear that the infection risk is higher there than in PD.

08.55-09.20 Mechanisms of Antibiotic Resistance: Lessons for the Nephrologist D Vogelaers, Gent, BelgiumGuidelines for treatment of PD related peritonitis (and also for other infections in dialysed patients) cannot be made general in terms of type of antibiotic to choose, as local epidemiology and resistance patterns are key in the selection of type of antibiotic of choice. Knowledge and understanding of mechanisms of resistance of the different antibiotic classes is of importance in the selection process. What causes resistance? Which strategies to use to avoid resistance? What to do if we have MRSA or C. Difficile in PD patients?

09.20-09.40 More Lessons from the Paediatric Peritonitis Registry F Schaefer, Heidelberg, Germany

09.40-10.05 Hepatitis Viruses and Peritoneal Dialysis M Jadoul, Brussels, BelgiumHepatitis (both B and C) remain problematic in some European countries, and remain a threat to the individual patient on RRT. The KDIGO guidelines do not give specific guidance on the relation PD-hep C. Can PD be of help? Should PD not be recommended in patients with hep C/B, or in centres where hep C/B is present? What to do with Hep C/B patients (waste handling, treatment)?

10.05-10.30 A Culture for PD P Rutherford, Wallisellen, SwitzerlandCulture negative peritonitis is an important risk factor for technique failure. What can we do to decrease the prevalence of “culture negative” peritonitis? What types of culture methods, or other diagnostic tools should we use to detect the responsible micro-organisms of peritonitis/tunnel infection?

Erasme Hall




10.30–11.00 Tea/Coffee Exhibition Foyer

11.00–13.00 Clinical Practice Session II

Increasing Technique Success: Preventing and Treating the Complications of PD

Chairs: E Goffin, Brussels, Belgium; O Heimburger, Stockholm, Sweden

11.00-11.20 Catheter Placement and Displacement A Slingeneyer, Montpellier, France Access to the peritoneal cavity is key to good PD. Technical problems related to catheter dysfunction such as dislocation, or obstruction, decrease adequacy and QoL. This session deals with different methods for catheter placement and approach to, and correction of, dislocated catheters.

11.20-11.40 Sleep Disorders in CKD Stage 5 I Mucsi, Budapest, HungarySleep apnoea is more prevalent than previously thought. PD might negatively impact on sleep apnoea: data, solutions.

11.40-12.00 The Role, Timing and Technique of Surgery for Encapsulating Peritoneal Sclerosis T Augustine, Manchester, UKWhat is the ideal treatment for encapsulating sclerosing peritonitis? Can surgery be life saving?

12.00-12.20 Severe and Relapsing Peritonitis B Issad, Paris, FrancePeritonitis remains a leading complication of PD and sometimes is associated with considerable morbidity. In most cases peritoneal infections are more benign and treated effectively by local specific antibiotic therapy. But in some cases peritonitis may be severe and relapsing. The infection fails to respond to medical treatment and surgical exploration occasionally reveals severe lesions. The purpose of this presentation is to discuss about the assessment of patients who fail to demonstrate clinical improvement and how to manage episodes of peritonitis caused by more aggressive micro-organisms (eg- s aureus, enteric g negative, Fungal peritonitis) prognosis, removal catheter and we focus on prevention relapses, because they are harmful for the long term preservation of the peritoneal depurative capacities.

12.20-13.00 Diagnosis and Treatment of Coronary Artery Disease in CKD stage 5: Can We Do Better? A De Vriese, Bruges, BelgiumMore than 50% of our patients die from cardiovascular causes, most of them because of coronary disease. Nevertheless, it is clear that cardiovascular disease is undertreated and underdiagnosed in CKD/RRT patients. How should we diagnose coronary disease, how should we treat (medication, PCI with our without stent, CABG) and what is the outcome. Place of aspirin, statins, beta blocking agents. Should also include pre-TX cardiac investigations.

Erasme Hall

13.00–14.00 Lunch/Posters/Exhibition (Lunch can be taken into the auditorium for the Gambro symposium)

Exhibition Foyer

Sunday 11th October continued


18



13.15-14.45 Industry Symposium IV

Dialysis Opinion Symposium on Innovations in PDA survey with focus on the need for future innovations in PD was conducted at the ISPD Congress in Istanbul, 2008. Responses were collected from over 800 nephrology professionals. The result will be presented and discussed by a group of experts including Dr Wim van Biesen, Professor Simon Davies, Dr James Heaf and Dr Ingrid Ledebo.

Erasme Hall

13.00-14.15 Poster Session II

A selection of the best posters will be discussed in a walking tour of the poster area and will be lead by: Clinical PD - Posters: P38-P73T Ulinski, France ; J Chanliau, France; M Dratwa, Belgium

Dialysis Solutions - Posters: P74-P90R Krediet, The Netherlands; B Faller, France

Infection - Posters: P91-P105F Schaefer, Germany; E Boulanger, France Biology Membrane & Function - Posters: P106-P108 & P146B Rippe, Sweden & D Uelingher, Switzerland

Ground Floor

14.45–15.45 Mini Symposium 2

Gastro-Intestinal and Feeding Problems in PD PatientsChairs: PY Durand, Quimper, France; G. Gahl, Berlin, Germany

There is a poor appreciation of the symptoms of advanced CKD. This session will look at the evidence base for the prevalence of uremic symptoms, how they should be measured and identified and consider non-dialysis methods for their control.

14.45-15.15 Understanding the Symptoms of Patients with Advanced CKDF Murtagh, London, UK

15.15-15.45 Upper Gastro-Intestinal Symptoms in PD: What, Why and How to Treat? B Bammens, Leuven, BelgiumDelayed gastric emptying can cause reflux, and nausea, and poor appetite in PD patients. What are the underlying pathphsyiological mechanisms, and how can we avoid/treat the problem.

Salle Schuman





14.45-15.45 Mini Symposium 3

Modelling the Membrane Without Equations Revisited: The Role of The Interstitium

Moderator: S Davies, Stoke on Trent, UK

Interactive Debate Featuring B Rippe, Lund, Sweden and S Davies, Stoke on Trent, UKWhat is the most optimal way to test and describe the peritoneal membrane in relation to transport of solutes. Should we use different tests for different situations, e.g. diagnostic vs prescription management? What is the place of available software? What is the role of the interstitium, and how do we integrate this in the existing membrane evaluation tests? This will be a practical session using interactive demonstrations to illustrate points.

Erasme Hall

15.45-16.15 Tea/Coffee Exhibition Foyer

16.15-18.15 Clinical Practice Session III

PD Adequacy: Beyond Small Solute Clearance Chair: C Verger, Pontoise, France

Sodium removal is of importance to maintain fluid balance in PD patients. How can we increase (peritoneal) solute removal in PD? Use of low sodium solutions, use of icodextrin, but also avoidance of sodium sieving should be discussed. Special focus will be given also on the measurement of sodium dialysate.

16.15-16.45 Holistic View on Adequate PD W Van Biesen, Gent, BelgiumPD adequacy is far more than just obtaining ‘small solute clearance’. Many other factors, such as volume control, nutrition, anaemia are of importance. Also avoidance of toxicity should be taken into account.

16.45-17.15 Which Solutes should we Target and is their Removal Different in PD vs HDR Vanholder, Gent, BelgiumWhen talking about “adequacy” solute removal is one of the major topics. It is however not quite clear which uremic toxins we should remove. It is also clear that different molecules have a different kinetic behaviour. How can PD and HD be compared in terms of solute removal patterns? Are there measures that can be used consistently both in PD and HD?

17.15-17.35 Sodium Removal in PD Patients P Freida, Cherbourg, France

17.35-17.55 Kinetic Modelling in PD: The Way to Improve Prescription? D Uehlinger, Bern, SwitzerlandUnderstanding the peritoneal transport physiology is not easy, and translating it into an adequate prescription is sometimes cumbersome, as many conflictive mechanisms play a role. Can computer software (kinetic modelling) be of help in the prescription, and how, and what are the potential pitfalls?

17.55-18.15 How to Evaluate and Improve Nutritional StatusD Fouque, Lyon, FranceNutritional status is an important marker of adequacy. Which investigations should we use to evaluate nutritional status of our patients, and what can we do to improve it? Dietary instructions, special feeding/food? Anabolic agents? Differences between HD-PD? Practical recommendations!!

Erasme Hall



20



16.15-18.15 Free Communications II

Ultrafiltration, Membrane Biology Including Sclerosis, SolutionsChairs: J D Williams, Cardiff, UK; F Schaefer,Heidelberg, Germany

16.15-16.27 - O-6 Indices of Cardiac Dysfunction in Peritoneal Dialysis Patients are Associated with Relative Increases in Intravascular Volume Rather than Extracellular Water Relative to Total Body Water Kay Tan, Biju John, Frauke Wenzelburger, Yu Ting Tan, Eveline Lee, John E Sanderson, Simon J Davies

16.27-16.39 - O-7 Nutritional Assessment using Body Composition Monitoring in Peritoneal Dialysis Patients. Variables Determining Body Mass, Fat Tissue and Lean Tissue IndexAdrian Covic, Wim van Biesen, Stanley Fan, Kathleen Claes, Monika Lichodziejewska-Niemierko, Christian Verger, Jürg Steiger, Volker Schoder, Adelheid Gauly, Rainer Himmele

16.39-16.51 - O-8 Twenty-Four-Hour Ultrafiltration Efficiency of Combined Glucose and Icodextrin Peritoneal Dialysis (Pd) SolutionsAlp Akonur, John K. Leypoldt

16.51-17.03 - O-9 The Extracellular Water Corrected for Height Predicts Technique Survival in Peritoneal Dialysis PatientsMeltem Sezis Demirci, Cenk Demirci, Hamad Dheir, Erhan Tatar, Ozkan Gungor, Mumtaz Yilmaz, Gulay Asci, Ali Basci, Ercan Ok, Mehmet Ozkahya

17.03-17.15 - O-10 Longitudinal Analysis of Solute and Fluid Transport in Peritoneal Dialysis Patients: The Conventional Versus a More Biocompatible Pd Solution Annemieke Coester, Watske Smit, Dirk Struijk, Raymond Krediet

17.15-17.27 - O-11 Free Water Transport in Children on Peritoneal dialysis Varies with Different Types of Dialysis Solution and with Time on Peritoneal Dialysis Renske Raaijmakers, Watske Smit, Annemieke Coester, Raymond Krediet, Cornelis Schroder

17.27-17.39 - O-12 Encapsulating Peritoneal Sclerosis in Patients on Peritoneal Dialysis: A Single-Center ExperienceValerio Vizzardi, Massimo Sandrini, Luigi Manili, Giuseppe Mazzola, Francesca Valerio, Laura Econimo, Giuliano Brunori, Giovanni C Cancarini

17.39-17.51 - O-13 Development of a Uremic Peritoneal Infusion Rat Model for Encapsulating Peritoneal SclerosisAnniek Vlijm, Denise E. Sampimon, Marijke de Graaff, Dirk G. Struijk, Raymond T. Krediet

17.51-18.03 - O-14 Characterization of Peritoneal Alternatively Activated Macrophages (aam): Implications for a Role in Peritoneal Membrane FibrosisRafael Selgas, Teresa Bellon, Virginia Martinez, Baltasar Lucendo, Gloria Del Peso, Maria Jose Castro, Luiz Aroeira, Rafael Sanchez-Villanueva, Auxiliadora Bajo

18.03-18.15 - O-15 Reduced Residual Renal Function is Associated with Endothelial Dysfunction in Patients Undergoing Peritoneal Dialysis Seung Hyeok Han, Ea Wha Kang, Hyang Sook Yoon, Shin-Wook Kang, Dae Suk Han

Tivoli II





16.15-17.45 Mini Symposium 4

PD and TransplantationChairs: P Harden, Oxford, UK; J P Ryckelynck, Caen, France

16.15-16.45 Impact of Pre-transplant Modality on OutcomeJP Ryckelynck, Caen, FranceImpact of pre-TX strategies on outcome; should include PD vs HD, but also probability for TX, EPS after TX?

16.45-17.15 PD in the Failed Transplant Patient V Jassal, Toronto, CanadaImmunosuppression in PD patients, transport status, outcome, outcome PD vs HD, prophylaxis.

17.15-17.45 Impact of CKD Stage 4/5 in the Failing Transplant: The Forgotten Cohort? P Harden, Oxford, UKThe failing transplant patient is often neglected in the pre-ESRD care. There can be an important role for good CKD stage 4 care in this patient group however.

Salle Schuman

18.30 Limited Coaches Depart for St Paul Church (optional concert)

19.00-20.00 Concert in St Paul Church provided free by the City of Strasbourg- Société des Cors de Chasse de Strasbourg-Neudorf Chorale CantaliaDaniel Maurer - Organiste



22



Monday 12th October 200907.30-12.4507.30-12.45

09.00-11.30


Exhibition & Internet Cafe Open


Exhibition Foyer

Masterclasses A3/B3/C3(by invitation only)

07.45-08.30 Theme A3: Clinical Epidemiology and Clinical Design D Evans, Paris, France

07.45-08.30 Theme B3: Pre-Dialysis, Education & PreparationWim Van Biesen, Gent, Belgium

07.45-08.30 Theme C3: Peritoneal Morphology O DeVuyst, Brussels, Belgium

Kleber

Gutenberg

Rohan

09.00–11.00 Symposium IV

Basic Science Fibrosis or Inflammation?Chair: D Johnson, Brisbane, Australia; E Boulanger, Lille, France

09.00-09.20 ET’s and PETS: Animal Models for PD in Europe P Terwee, Amsterdam, The NetherlandsWhere do we stand with animal models in Europe? Can animal models really increase our understanding of the peritoneal membrane, and how far are can these data be translated to human physiology? Pitfalls of animal models in PD.

09.20-09.45 Genetically Modified Mice: Inborn Messages for PD?O Devuyst, Brussels, BelgiumCan genetically modified (knock out) animals (mice) have a role in PD research?

09.45-10.10 Inflammation is Not Only a Marker But Also Plays a Causative Role in Clinical Putcomes O Heimburger, Stockholm, SwedenThis talk should give an overview on how inflammation is the common pathway both in deterioration of the peritoneal membrane, as for the cardiovascular and malnutrition outcome of patients with ESRD. What can we do to avoid/block the effects of inflammation in our patients? How to measure inflammatory status in our patients?

10.10-10.35 Our Current Understanding of Peritoneal Damage During PD: Fibrosis is the Key J Witowski, Poznan, PolandThere is evidence that a lot of damage of the peritoneal membrane is not related to inflammation, but rather to (in)direct stimulation of fibrosis by pathways other than inflammation, eg, TGF beta

10.35-11.00 Chameleon Cells: Epithelial to Mesenchymal Transition R Selgas, Madrid, SpainThe transition of cells from one cell type to another is a fascinating process. What are the relevant messages from our current understanding of these processes to PD. Can eventually be extended also to the transition to osteoblastic cells of vascular smooth muscle cells. Focus should thus be on the molecular and cellular mechanisms behind the observed EMT, rather than on the observations themselves.

Erasme hall




09.00–11.00 Symposium V

PD from a Broader View: What the Different French Nephrology Societies can Contribute to PD

Chairs: J Chanliau, Nancy, France; JP Ryckelynck, Caen, France

This session should allow the different societies that constitute the local organising committee to express their view on how they can contribute to “home dialysis” and/or PD.

09.00-09.30 Muscle Mass in PD Patients C Verger, Pontoise, France

09.30-10.00 Dry Weight Assessment in PDF Vrtovsnik, Paris, France

10.00-10.30 Optimal APD Prescription PY Durand, Quimper, France

10.30-11.00 Cardio Vascular Risks in Children in ESRF T Ulinski, Paris, France

Salle Schuman

11.00-11.30 Tea/Coffee (Exhibition, Internet Café & Posters close at 11.30) Exhibition Foyer

11.30-12.30 Free Communications III

Basic Science and InfectionChairs: A Ekstrand, Helsinki, Finland; M Dratwa, Brussels, Belgium

11.30-11.42 - O-16 Effects of BicaVera® Dialysate for Peritoneal Dialysis on the Epithelial-to-Mesenchymal Transition (EMT) of the Mesothelial Cell (MC) Jose Antonio Sanchez-Tomero, Antonio Fernandez-Perpen, Maria Auxiladora Bajo, Maria Luisa Perez-Lozano, Gloria Del Peso, Pedro Albar, Abelardo Aguilera, Antonio Cirugeda, Manuel Lopez-Cabrera, Rafael Selgas

11.42-11.54 - O-17 Functional Relevance of Vegf (Vascular Endothelial Growth Factor) and Vegf Receptors (Vegfrs) Switch During Peritoneal Dialysis-Induced Epithelial Mesenchymal Transition (Emt) of Mesothelial Cells Maria Luisa Perez-Lozano, Jose Antonio Jimenez-Heffernan, Abelardo Aguilera, Pilar Sandoval, Patricia Albar, Maria Auxiliadora Bajo, Jose Antonio Sanchez-Tomero, Rafael Selgas, Manuel Lopez-Cabrera

11.54-12.06 - O-18 Relationship Between Solute Transport Status and Inflammatory Cytokines in Peritoneal DialysisMark Lambie, James Chess, Kit Huckvale, Nick Topley, Simon Davies

12.06-12.18 - O-19 Ultrasonographic Evaluation of Peritoneal Membrane Thickness and Comparison with the Duration and Effectiveness of Peritoneal Dialysis Gokhan Temiz, Sultan Ozkurt, Gul Mukerrem, Garip Sahin, Nevbahar Akcar Degirmenci, Ahmet Ugur Yalcin

12.18-12.30 - O-20 Human γδ T Cells Drive the Acute Inflammation in Bacterial Infection: Implications for PD-Related Peritonitis Matthias Eberl, Martin S Davey, Gareth W Roberts, Chan-Yu Lin, James Chess, Holly Ciesielczuk, Rob Shorten, John D Williams, Nicholas Topley, Bernhard Moser

Tivoli II

Monday 12th October continued


24



11.30-12.30 Mini Symposium V

Future Developments in PDChairs: R Krediet, Amsterdam, The Netherlands; J D Williams, Cardiff, UK

11.30-11.50 High flow PD: Still Viable? A Vychytil, Wien, AustriaHigh flow PD has been advocated as a way to improve (small solute) clearance, but technical problems, and the understanding that small solute clearance is probably not so important after all, have decreased the impetus of research in this area. Is there still room for further development of this type of treatment?

11.50-12.10 New Peritoneal Dialysis Solutions: Which Way to Go? S Fan, London, UKIs there room for new PD solutions? If yes, which should be the properties of such a solution, and what are potential candidates for modification?

12.10-12.30 PD and Absorption Techniques: Brothers in Arms Towards a Wearable Artificial Kidney? R Krediet, Amsterdam, The NetherlandsPD is the first really “wearable artificial kidney”. However, newer systems have been described using adsorption techniques, so that the dialysate can be recycled. Is this a future way to go?

Erasme Hall

11.30-12.30 Mini Symposium VI

Transition from Paediatric to Adult NephrologyChairs: M Tsimaratos, Marseille, France; P Harden, Oxford, UK

11.30-11.50 What the Adult Nephrologist Should Know About Congenital Nephrological Disease M Tsimaratos, Marseille, FranceDue to better survival, youngsters with “strange congenital disease” will come up to the adult nephrology clinic. What does the adult nephrologist need to know to take care of these teenagers?

11.50-12.10 Intensive and Daily Dialysis M Fischbach, Strasbourg, France Results of the experience in Strasbourg with intensive HD and the impact on treatment approach in children; how to plan treatment in the long run; Is as soon as possible TX always the best option?

12.10-12.30 Transition and its Problems P Harden, Oxford, UKThe transition from the protected paediatric ward to the hostile environment of adult nephrology care takes place during the turmoil of puberty and identity problems. This causes a lot of problems, with a strong negative impact on outcomes.

Salle Schuman

12.30-12.45 Prizes & Closing RemarksChairs: J D Williams, Cardiff, UK; M Fischbach, Strasbourg, France

Erasme Hall

Monday 12th October continued




Additional InformationExhibition & Internet Café Friday 9th October 2009 16.30 – 21.00 Saturday 10th October 2009 10.00 – 17.30 Sunday 11th October 2009 10.30 – 17.30 Monday 12th October 2009 09.00 – 11.30

Please note that free WiFi access is also available in the Agora Foyer in the Congress Centre.

Registration Desk Friday 9th October 2009 10.30 – 18.00 Saturday 10th October 2009 07.00 – 18.45 Sunday 11th October 2009 07.30 – 18.15 Monday 12th October 2009 07.30 – 12.45

Congress Etiquette Mobile phones should be switched off or placed on ‘silent’ during scientific symposia.

Thank you for your co-operation.

Please also respect speakers and other delegates and refrain from talking once a scientific symposium has started. If you are planning to move between simultaneous symposia please sit near the end of rows and leave the rooms quietly.

Registered Delegates If you are a fully registered delegate for the Congress, the following is included:

• Attendance at the scientific sessions and entry to the exhibition

• Delegate Bag and contents

• Name Badge – This should be worn at all times

• Attendance at the Welcome Reception (Friday 9th October 2009)

• Morning and Afternoon refreshment breaks including a sandwich lunch. Please note that lunch will not be provided on Friday or Monday.


26



Accompanying Persons Please note that Accompanying Persons will not have access to Scientific Sessions or teas/coffees or lunches. However Accompanying Persons can attend the Welcome Reception. Tickets will cost 25 Euros per person. An on-site booking facility will be available at the registration desks.

Certificate of Attendance Certificates of attendance will be provided on request from the registration desks.

Insurance The organisers will accept no liability for personal injuries sustained by or for loss or damage to property belonging to the meeting participants, either during or as a result of the meeting or during any event.

Posters Poster presentations will be displayed throughout the conference:

Poster Session I ANIMOD Posters: P1 - P5 Cardiovascular Posters: P6 - P15 Clinical PD Posters: P16 - P37 Paediatrics Posters: P109, P143 - P145 Other Posters: P124 - P142

Poster Session II Clinical PD Posters: P38 - P73 Dialysis Solutions Posters: P74 - P90 Infection Posters: P91 - P105 Biology Membrane & Function Posters: P106 - P108, P146

Speaker Preview Room This will be located on the first floor in the Salon President. All presenters (invited speakers/free communications/commercial symposia) should hand in their presentation on disk/CD rom/memory stick a minimum of 4 hours prior to their session.

Please do not bring your own laptop as computers will be provided.

Opening Times: Friday 9th October 2009 10.00 – 18.00 Saturday 10th October 2009 07.00 – 18.45 Sunday 11th October 2009 07.30 – 18.15 Monday 12th October 2009 07.30 – 12.45




Exhibitors & Sponsors

Address: 62 bd Victor Hugo 92523 Neuilly sur Seine Cedex Contact: Clémence MARQUE Tel: 01 40 88 27 00 Fax: 01 40 88 27 99 Email: [email protected] Website: www.amgen.com

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disorder, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

Address: 1620 Waukegan Road, McGaw Park, IL 60085 Tel: +1888 229 0001 Fax: +1888 229 0020 Website: www.baxter.com

Baxter Healthcare Corporation is a global diversified healthcare company, bringing together Science, Systems, Solutions, and Support into a full Dialysis offering. For over 50 years, Baxter has conducted extensive research and development, and is committed to bringing to market product innovations that help to advance the treatment of renal disease including the first and only peritoneal dialysis solutions with non-glucose osmotic agents.

Address: Else-Kröner-St 1 61352, Bad Homburg v.d.H, Germany Contact: Yasmin Rachid Tel: +49-6172-6092285 Fax: +49-6172-6092586 Email: [email protected] Website: www.fmc-ag.com

Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. Through its network of more than 2,440 dialysis clinics worldwide, Fresenius Medical Care provides dialysis treatment to more than 187,400 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.



28



Address: Scheelevägen 34 220 10 Lund Sweden Contact: Anki Davidson Tel: +46 46 16 92 12 Fax: +46 46 16 91 75 Email: [email protected] Website: www.gambro.com

Gambro has been pioneering solutions for patients in Chronic and Acute Therapies for more than 45 years. With you and your patients as our inspiration, we are constantly seeking ways to advance the science of dialysis. The result is innovative products that will support your success. Gambro – Your home of INNOVATION – You inspire, We innovate.

Address: Gooimeer 10, 1411 DD, Naarden, The Netherlands Contact: Suzanna van Straaten Tel: +31 (0) 35 699 8601 Fax: +31 (0) 35 699 1453 Email: [email protected] Website: www.genzyme.com

Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases, with many established products and services helping patients in nearly 100 countries. Genzyme’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing.

Address: Le Palatin – 30, rue de Valmy – La Défense 12, 92936 Paris La Defense Cedex, France Contact: Jocelyne Azoulay Tel: +33 1 41 97 65 96 Fax: +33 1 41 97 64 61 Email: [email protected] Website: www.novonordisk.com

Novo Nordisk is a health specialist pharmaceutical company and one of the worldwide leaders in the diabetes treatment. The company is also on the first position in the areas like Growth Hormone Deficiency and Haemostatic treatments. Novo Nordisk produces and markets pharmaceutical products and services. Based in Denmark, Novo Nordisk employs around 27 068 persons in 80 countries and markets its products in 179 countries.

For further information, refer to our website: www.novonordisk.com.

www.europd.com




Address: 23-25 Avenue Dr Lannelongue, F-75668 Paris Cedex 14 Website: www.pfizer.com

Pfizer is the world’s largest research-based biomedical and pharmaceutical company. Our corporate headquarters are located in New York. Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals.

Address: Hampshire International Business Park, Basingstoke, Hampshire, RG24 8EP, UK Contact: Pratul Unadkat Tel: +44 (0) 1256 894335 Fax: +44 (0) 1256 894706 Email: [email protected] Website: www.shire.com

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist PD physician. The company’s portfolio of products for the treatment of patients with renal diseases include FOSRENOL®, a non-calcium based phosphate binder for the management of Hyperphosphataemia and REPLAGAL®, for the treatment of Fabry Disease.


30



Congress Centre Plans

www.eraedta2010.org

XLVII ERA-EDTA CONGRESSJUNE 25-28, 2010

Munich, Germany

Kandinsky, an Artist in Munich Fixe 1935, Wassily Kandinsky© VG Bild-Kunst, Bonn 2009

AD 14,8x21.indd 1 20-07-2009 7:14:02

First Floor

Ground Floor


30

www.eraedta2010.org

XLVII ERA-EDTA CONGRESSJUNE 25-28, 2010

Munich, Germany

Kandinsky, an Artist in Munich Fixe 1935, Wassily Kandinsky© VG Bild-Kunst, Bonn 2009

AD 14,8x21.indd 1 20-07-2009 7:14:02EPD Final Prog A5.indd 31 29/9/09 11:37:24

Pioneers in PD. Partners in trust.

Confidence, competence and commitment are key factors in your efforts to improve patients’ quality of life.

Baxter has developed almost every major milestone in PD therapy and by doing so has earned the trust of physicians worldwide. Because we stand with you in support of your practice and your patients, you can confidently prescribe effective peritoneal dialysis that delivers good quality of life.

Baxter. First from the start.Copyright 2009 Baxter International Inc. RR-RD-209 10/09

BXT-192D EuroPD Leadership Ad.indd 1 9/1/09 10:14:00 AM


Documents

EuroPD 2009 - PD For Alleuropd2017.crushdigital.co.uk/wp-content/uploads/... · Overview of the anatomy of the peritoneal membrane, basic understanding of small solute transport and